We’re excited to announce that Idem has been ranked among the Top 30 language service providers in North America by Common Sense Advisory, an independent market research firm. With the global market for translations now exceeding $40B, Idem is proud to be a part of our industry’s long-running growth and we are thrilled to play an integral part in the translations required to bring new medical devices and therapies to the patients who need them across the globe.
Do you always have to sacrifice quality for the sake of your translation budget? Or break that budget to get a good translation?
Definitely not! While cost and quality are a common balancing act, a little process planning can help you achieve both.
Have your cake and eat it, too: Download the brief!
Fed up with translation headaches? If your current translation vendor is causing you more problems than they fix, it’s time for a change.
We looked at the top five reasons to avoid switching suppliers. And we found that they aren’t that scary after all! Read our brief and see if you agree.
Don’t settle for a mediocre vendor: Download the brief!
The following is an interesting post from a LinkedIn connection. Have you built into your study the participation of diverse groups based on race, ethnicity, and gender? Do you have translated documents to support those populations? Many language providers out there claim to provide specialized translations specifically for life science initiatives, yet few fulfill the necessary requirements to pass muster with your Regulatory Affairs team.
Source: Fomat Medical Research
Hispanic cancer patients rarely participate in clinical trials, but researchers want to tailor a Spanish DVD to help change this. To create a relevant educational tool, Moffitt Cancer Center researchers investigated why awareness of and participation in trials are so low in this population.
Using focus groups with 36 Spanish-speaking cancer survivors from Tampa and Puerto Rico, researchers found that a language barrier, as well as a cultural idea that only doctors, not patients, guide treatment decisions, may help account for low participation rates.
Looking for ways to improve knowledge and participation for Hispanic patients, the researchers used feedback from the focus groups to help develop a Spanish booklet and video to educate and empower patients to participate in treatment decisions.
The study was published online in May by the Journal of Health Communication: International Perspectives.
The 45.5 million Hispanics living in the United States are the nation’s fastest growing ethnic group, and there is a need to develop health care educational materials that target their language and culture. These educational materials should not be merely translated from English, the researchers said, but should be adapted to meet the group’s informational needs in a culturally appropriate way.
Palo Alto, CA (PRWEB) January 23, 2017
Idem Translations, a provider of translation and localization services for life science companies, has achieved ISO 17100:2015 certification following a comprehensive audit performed by international testing and inspection organization, TÜV SÜD America. ISO 17100 is the globally recognized standard that establishes guidance for critical processes within translation, quality of service, delivery requirements, translator evaluation and selection, technical resource specifications and general management guidelines for translation service providers. ISO 17100:2015 replaces the previous European standard for translation services, EN 15038:2006, thus addressing changes within the industry.
Idem Translations is among the first U.S. translation providers specialized in life science to receive
ISO 17100 certification by TÜV SÜD America. Idem is proud to have successfully passed TÜV SÜD America’s stringent auditing procedures, validating the company’s strict approach for producing superior translated content for its clients.
“Our clients work in regulated industries where safety and traceability are the very foundation of their development and manufacturing processes. They rely on Idem Translations to ensure that translation processes follow the same quality control steps that are both repeatable and auditable,” said Jessica Alexander, Vice President of Quality & Operations at Idem Translations. “Updating our ISO certification to 17100 signals our commitment to continually reduce risk throughout the translation process, and provides a guarantee to clients that translation will be one less thing they’ll have to worry about.”
“Companies like Idem Translations that invest in multiple ISO standards like ISO 9001, ISO 13485 and ISO 17100 recognize the importance of certification not just to clients but to the overall mission of continuous process improvement,” said Dr. Christopher Devine, President of Devine Guidance International. “More than just standards, these certifications mean that the company is focused on meeting tough industry requirements that result in exceptional vendor care.”
Are translations a constant pain point for your team? Maybe you’re dissatisfied with your current vendor, but you’re afraid of all the headaches that go with onboarding a new one?
You deserve a translation vendor who exceeds your expectations. Read our recommendations to prepare yourself for a smooth transition.
Get the translation vendor you deserve: Download the brief!
Translation is expensive. Translation is time-consuming. So how can you cut costs and reduce your translation timelines?
We’ve put together our top ten stumbling blocks in translation to help. Because a few simple fixes can have dramatic long-term benefits.
Make your documentation more “translatable”: Download the brief!
Calling all regulatory professionals!
Idem will be exhibiting at RAPS Convergence in Santa Clara, California, September 17-20. You won’t want to miss this year’s fantastic lineup. If you’re interested in sessions that address updates to regulations and guidance around the globe, this is a perfect opportunity to stop by and speak to us about your future translation needs.
Let’s put our heads together at RAPS and see how we can make translations the easiest part of your job! Schedule a meeting with us today.
We’re giving away a Fitbit, so stop by for your chance to win. See you there!
Translate your content using specialist medical linguists. Below is a quick overview of Idem’s services for companies in the medical device and pharmaceutical industries. We offer comprehensive translation services, including back translation, reconciliation, linguistic review, quality assurance, DTP and more.
Crowdfunding has become a household word among technology companies, and is now making its way to the forefront of the medical device industry. Sites like Kickstarter and Indiegogo are seeing a rise among would-be investors getting in on the ground floor of these ventures, with the promise of blockbuster returns. Certain sites are targeted specifically to the medical device developer community; examples such as Crowdacure aim exclusively on medical device development.
The reasons for this burgeoning activity are essentially the same as what one might find in technology: investor appetite for early-stage development is on the wane since so many of them would prefer to invest in ventures whose devices are closer to market release. This, coupled by the FDA’s perceived inability to move devices more rapidly through regulatory channels results in device manufacturers’ willingness to seek approval with offshore regulatory bodies (particularly the EU). What’s more, researchers and early-stage device manufacturers are trying to rein in costs so as to make their technologies affordable for everyone. Quite often, it’s the only way for companies to fund research and development for non-traditional diseases or conditions that aren’t a target for regular funding pathways, either because the population affected isn’t large enough or vocal enough.
The funding path from unorthodox sources like the ones described is, of course, fraught with risk. A multitude of eager investors may hedge their bets on therapies that will never see the light of day or receive FDA clearance, and there’s no specific language to date that addresses the legal implications of such a practice. Certainly the FDA is in no hurry to make a ruling on how products are financed, limiting its reach to issues that might pose a threat to public safety.
It’s easy to see the attraction for the medical device startups to go this route, and it could be a faster, more economical method for getting much needed therapies out to the public sooner and more affordably. What are your thoughts about this practice? Are you currently involved in or thinking about a crowdfunded approach to funding your medical device development?
Fatal error: Call to undefined function twentythirteen_paging_nav() in /home/idem/public_html/wp-content/themes/alt_idem/category.php on line 31